• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血小板活化因子(PAF)受体拮抗剂L-652,731对绵羊PAF和补体诱导的肺动脉高压的影响。

Effects of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep.

作者信息

Smallbone B W, Taylor N E, McDonald J W

机构信息

Department of Medicine, University of Western Ontario, London, Canada.

出版信息

J Pharmacol Exp Ther. 1987 Sep;242(3):1035-40.

PMID:2821222
Abstract

Thromboxane-mediated pulmonary hypertension, pulmonary edema, arterial hypoxia and pulmonary leukostasis occur in response to the infusion of plasma containing zymosan-activated complement (ZAP) in sheep. Platelet-activating factor (PAF) is a potential mediator of some of these effects. We investigated the effects of PAF infusions in unanesthetized sheep and the effects of the PAF receptor antagonist L-652,731 [trans-2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran] on the hematologic, hemodynamic and biochemical alterations produced by infusions of both ZAP and PAF. Infusions of 2 to 20 micrograms of PAF in 0.25% ovine serum albumin-saline produced pulmonary hypertension, hypoxia and dose-dependent thrombocytopenia, neutropenia and thromboxane synthesis. The effects of a 2 micrograms of PAF infusion were both qualitatively and quantitatively similar to those produced by a ZAP infusion. Pretreatment with aspirin (10 mg/kg) protected the sheep against the pulmonary vascular response to 20 micrograms of PAF and blocked completely the thromboxane synthesis. L-652,731 at a dose of 8 mg/kg blocked completely the neutropenia, thrombocytopenia, thromboxane synthesis, pulmonary hypertension and hypoxia induced by 5 micrograms of PAF, but this protective effect was not observed in animals infused with ZAP. These results indicate that PAF is probably not a mediator of the neutropenia, thromboxane-mediated pulmonary hypertension and hypoxia which result from the infusion of ZAP into sheep.

摘要

在绵羊中,输注含有酵母聚糖激活补体(ZAP)的血浆会引发血栓素介导的肺动脉高压、肺水肿、动脉低氧血症和肺白细胞淤滞。血小板活化因子(PAF)可能是其中某些效应的介导物。我们研究了在未麻醉绵羊中输注PAF的效应,以及PAF受体拮抗剂L-652,731[反式-2,5-双(3,4,5-三甲氧基苯基)四氢呋喃]对输注ZAP和PAF所产生的血液学、血流动力学和生化改变的影响。在0.25%绵羊血清白蛋白盐水中输注2至20微克PAF会导致肺动脉高压、低氧血症以及剂量依赖性血小板减少、中性粒细胞减少和血栓素合成。输注2微克PAF所产生的效应在性质和数量上与输注ZAP所产生的效应相似。用阿司匹林(10毫克/千克)预处理可保护绵羊免受20微克PAF引起的肺血管反应,并完全阻断血栓素合成。剂量为8毫克/千克的L-652,731可完全阻断5微克PAF诱导的中性粒细胞减少、血小板减少、血栓素合成、肺动脉高压和低氧血症,但在输注ZAP的动物中未观察到这种保护作用。这些结果表明,PAF可能不是输注ZAP至绵羊体内所导致的中性粒细胞减少、血栓素介导的肺动脉高压和低氧血症的介导物。

相似文献

1
Effects of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep.血小板活化因子(PAF)受体拮抗剂L-652,731对绵羊PAF和补体诱导的肺动脉高压的影响。
J Pharmacol Exp Ther. 1987 Sep;242(3):1035-40.
2
Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.血小板活化因子(PAF)介导大鼠对可溶性免疫复合物的过敏反应。PAF受体拮抗剂L-652,731的研究。
J Immunol. 1986 Jun 15;136(12):4659-68.
3
Thromboxane synthesis by sources other than platelets in association with complement-induced pulmonary leukostasis and pulmonary hypertension in sheep.除血小板外的其他来源的血栓素合成与绵羊补体诱导的肺白细胞淤滞和肺动脉高压相关。
Circ Res. 1983 Jan;52(1):1-6. doi: 10.1161/01.res.52.1.1.
4
Effect of platelet-activating factor receptor antagonism on endotoxin-induced lung dysfunction in awake sheep.血小板活化因子受体拮抗作用对清醒绵羊内毒素诱导的肺功能障碍的影响。
Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1272-8. doi: 10.1164/ajrccm/142.6_Pt_1.1272.
5
Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.血小板活化因子(PAF)受体拮抗剂反式-2,5-(3,4,5-三甲氧基苯基)四氢呋喃(L-652,731)对大鼠体内PAF诱导反应的抑制作用
J Pharmacol Exp Ther. 1986 Dec;239(3):841-5.
6
Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.L-659,989的生化与药理学特性:一种血小板活化因子的超强效、选择性及竞争性受体拮抗剂
J Pharmacol Exp Ther. 1988 Aug;246(2):534-41.
7
Effects of verapamil on thromboxane synthesis and pulmonary hypertension in sheep.维拉帕米对绵羊血栓素合成及肺动脉高压的影响。
Clin Invest Med. 1986;9(3):145-9.
8
Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials.肾小球血栓素A2增强介导了血小板活化因子在兔肾毒性肾炎中的一些病理生理效应:来自生化检测和抑制剂试验的证据。
J Lab Clin Med. 1989 May;113(5):549-60.
9
trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor.反式-2,5-双-(3,4,5-三甲氧基苯基)四氢呋喃。一种口服活性的血小板活化因子特异性竞争性受体拮抗剂。
J Biol Chem. 1985 Dec 15;260(29):15639-45.
10
[Effect of corticosteroids, quinacrine and L-652, 731 on experimental aggregation of polymorphonuclear leukocytes induced by complement and platelet activating factor (PAF)].[皮质类固醇、奎纳克林及L-652,731对补体和血小板活化因子(PAF)诱导的多形核白细胞实验性聚集的影响]
Rev Esp Fisiol. 1988 Dec;44(4):407-12.

引用本文的文献

1
A novel complement C3 inhibitor CP40-KK protects against experimental pulmonary arterial hypertension via an inflammasome NLRP3 associated pathway.一种新型补体 C3 抑制剂 CP40-KK 通过炎症小体 NLRP3 相关途径保护实验性肺动脉高压。
J Transl Med. 2024 Feb 16;22(1):164. doi: 10.1186/s12967-023-04741-z.
2
A current view of G protein-coupled receptor - mediated signaling in pulmonary hypertension: finding opportunities for therapeutic intervention.肺动脉高压中G蛋白偶联受体介导信号传导的当前观点:寻找治疗干预机会
Vessel Plus. 2018;2. doi: 10.20517/2574-1209.2018.44. Epub 2018 Aug 30.